A pilot study to evaluate the effects of C1 esterase inhibitor on the toxicity of high-dose interleukin 2.

[1]  L. Thijs,et al.  C1-esterase inhibitor substitution in sepsis , 1992, The Lancet.

[2]  J. Baars,et al.  The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2. , 1992, British Journal of Cancer.

[3]  M. Atkins,et al.  Complement activation in cancer patients undergoing immunotherapy with interleukin-2 (IL-2): binding of complement and C-reactive protein by IL-2-activated lymphocytes. , 1991, Blood.

[4]  T. Eberlein,et al.  The systemic complement activation caused by interleukin‐2/lymphokine‐activated killer‐cell therapy of cancer causes minimal systemic neutrophil activation , 1991, International journal of cancer.

[5]  C. Hack,et al.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects. , 1990, Journal of immunology.

[6]  C. Hack,et al.  Proteolytic inactivation of plasma C1- inhibitor in sepsis. , 1989, The Journal of clinical investigation.

[7]  L. Thijs,et al.  A modified competitive inhibition radioimmunoassay for the detection of C3a. Use of 125I-C3 instead of 125I-C3a. , 1988, Journal of immunological methods.

[8]  M. Papa,et al.  Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[10]  H. Savage,et al.  Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa. , 1992, Archives of otolaryngology--head & neck surgery.